Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Why Biotech ETFs Surged In Monday's Trading Session

By Zacks Investment ResearchStock MarketsNov 27, 2019 07:06AM ET
Why Biotech ETFs Surged In Monday's Trading Session
By Zacks Investment Research   |  Nov 27, 2019 07:06AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

The NASDAQ Biotechnology Index gained 2.6% in the trading session on Nov 25. This compares favorably with the NASDAQ Composite Index’s rise of 1.3%, S&P 500 Index’s 0.8% and Dow Jones Industrial Average’s 0.7% on the same day. Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to drive the biotech market. The sector has also been benefitting from a flurry of positive news, including trial results and deal activities. Let’s see what could have possible triggered the upside (read: Biotech ETFs in Focus on Impressive Q3 Earnings Results).

FDA Approval

The FDA approved Global Blood Therapeutics, Inc.’s (NASDAQ:GBT) drug for treating sickle cell disease in adults and children aged 12 years or above on Nov 25. The shares of the company rose around 7% on the day. The drug will be marketed under the brand name of Oxbryta. With this development, the biotechnology sector has witnessed the approval of the second drug for treating sickle cell anaemia in recent days. Moreover, it has become the first drug to treat the primary cause of the disease instead of the symptoms. On Nov 15, Novartis AG (NYSE:NVS) received FDA approval for Adakveo to bring down the frequency of vaso-occlusive crises or pain crises in adult and paediatric patients aged 16 years and older with sickle cell disease.

New Merger-Acquisition Deal

Swiss drugmaker Novartis AG recently announced plans to buy cholesterol drug developer, The Medicines Company, for $9.7 billion. The acquisition will give Novartis access to Medicines Co.’s near-to-market heart drug — inclisiran. Medicines Co. is expected to submit the drug to the FDA for approval by the end of 2019. The company has high chances of getting a clearance from the authorities as it recently presented positive data confirming the efficacy of the drug.

Release of Positive Data

CRISPR Therapeutics (NASDAQ:CRSP) and its partner Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) recently announced encouraging preliminary safety and efficacy data from the ongoing phase I/II studies. Notably, the studies are evaluating the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders — sickle cell disease and adult transfusion-dependent b-thalassemia (TDT).

CRISPR Therapeutics and Vertex were each up 17% and 2.5%, respectively, on Nov 19, in response to the news. However, CRISPR lost some gains due to an underwritten public offering on the same day during after-hours trading (read: Genomics ETFs Surge on CRISPR's Gene Editing Progress).

Biotech ETFs in Focus

In the current scenario, we believe it is prudent to discuss a few ETFs which have considerably wide exposure to the companies discussed.

iSharesNasdaq Biotechnology ETF IBB

This fund seeks to provide exposure to U.S. biotechnology stocks and tracks the NASDAQ Biotechnology Index. It comprises 215 holdings. It has AUM of $7.5 billion and charges a fee of 47 basis points a year. The fund gained 2.5% in yesterday’s trading session (read: Top-Ranked ETFs That Crushed the Market in a Month).

VanEck Vectors Biotech ETF (LON:BBH)

The underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. It holds about 24 securities in its basket. Its AUM is $364.2 million and expense ratio is 0.35%. The fund gained 2.1% in yesterday’s trading session.


The fund seeks daily investment results, before fees and expenses, which match the S&P Biotechnology Select Industry Index. It holds about 115 securities in its basket. Its AUM is $4.02 billion and expense ratio, 0.35%. The fund gained 4.3% in yesterday’s trading session (read: Healthcare ETFs Win in October: Here's Why).

First Trust Amex Biotechnology Index FBT

The fund measures the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. It holds about 31 securities in its basket. Its AUM is around $1.73 billion and expense ratio is 0.57%. The fund gained 2.4% in yesterday’s trading session.

Want key ETF info delivered straight to your inbox?

Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>

Novartis AG (NVS): Free Stock Analysis Report

iShares Nasdaq Biotechnology ETF (IBB): ETF Research Reports

First Trust NYSE Arca Biotechnology Index Fund (FBT): ETF Research Reports

VanEck Vectors Biotech ETF (BBH): ETF Research Reports

SPDR S&P Biotech ETF (XBI): ETF Research Reports

Global Blood Therapeutics, Inc. (GBT): Free Stock Analysis Report

Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report

CRISPR Therapeutics AG (CRSP): Free Stock Analysis Report

Original post

Zacks Investment Research

Why Biotech ETFs Surged In Monday's Trading Session

Related Articles

Why Biotech ETFs Surged In Monday's Trading Session

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email